FDA
-
-
-
-
-
-
-
BriaCell expands Phase 3 breast cancer study to 79 clinical sites
-
-
-
-
-
-
-
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Study
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Reports Positive Survival Data in Advanced Metastatic Breast Cancer
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Reports Positive Breast Cancer Efficacy Data with Bria-IMT Immunotherapy Treatment
-
-
-
-
-
-
-
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
-
-
-
-
-
-
Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

